Can a new governor, an oligarch from the region, restore calm in the face of a depressed economy, corruption, and a pro-Russian political establishment?
Lamborghini, Ferrari, Maserati, McLaren, and Porsche are all popular among the filthy rich
The U.S. provides hope that much of the world could eventually avoid both malnutrition and excess nutrition
Microsoft's Xbox One sales need a big boost from exclusive game Titanfall
Comcast might please shareholders by spinning off some 3 million subscribers. How long could the new cable company survive independently?
Groups representing professional photographers prefer to develop ways to pay image creators in place of Getty's tolerance for Web embedding
DIsney's MyMagic+ technology may make a trip to Disney World more magical—or creep customers out
European MBA programs compete with top-tier U.S. schools for the best students at home and abroad
Research suggests that women may turn to entrepreneurship after 50 to support themselves in retirement
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."